Anti-CD18 mAb (Genentech/Roche).
Genentech and Roche are collaborating on the development of an anti-CD18 humanized monoclonal antibody (rhuMAb). Inhibition of leukocyte adhesion with antibodies to CD18 is proposed as a therapeutic intervention for indications with an inflammatory component resulting from a reperfusion injury. In June 2000, the company reported that the primary objectives of its phase II trial of the antibody were not met according to preliminary results of the 415-patient trial for the treatment of myocardial infarction [371173], although the company is currently undecided about the implications of the data, and plans to meet with investigators. In 1999, phase II studies for reperfusion injury in patients successfully treated with thrombolytics were planned; enrollment was expected to finish in the third quarter of 1999 [317276]. In February 1999, Lehman Brothers predicted the drug had a 30% probability of reaching market. Assuming a successful launch, Lehman Brothers analysts estimated peak sales would occur in 2009, with sales at that time of 100 million dollars [319225].